Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease

Trends in Neurosciences

Volumn 38, Issue 10, 2015, Pages 621-636

  Mhatre, Siddhita D ^a,b   Tsai, Connie A ^a,b   Rubin, Amanda J ^a,b   James, Michelle L ^a   Andreasson, Katrin I ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; A peptide; Braak stages; Epigenomics; GWAS; Microglia; Tau phosphorylation; Transcriptomics

Indexed keywords

ABC TRANSPORTER; ABCA7 PROTEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CD33 ANTIGEN; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; MS4A PROTEIN; MYOCYTE ENHACER FACTOR 2C; MYOCYTE ENHANCER FACTOR 2; SYNAPTOJANIN; TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG;

ADULTHOOD; ALZHEIMER DISEASE; BRAIN DYSFUNCTION; BRAIN REGION; DISEASE COURSE; ENTORHINAL CORTEX; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; ANIMAL; BRAIN; IMMUNOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; MICROGLIA;

EID: 84943259879     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2015.08.006     Document Type: Review

References (136)

1. Hebert L.E., et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
2. Braak H., et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011, 70:960-969.
3. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
4. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278.
5. Nelson P.T., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71:362-381.
6. Thal D.R., et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
7. Sperling R., et al. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 2014, 84:608-622.
8. Vitek M.P., et al. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 2009, 30:1350-1360.
9. Cudaback E., et al. Apolipoprotein E isoform-dependent microglia migration. FASEB J. 2011, 25:2082-2091.
10. Cudaback E., et al. APOE genotype-dependent modulation of astrocyte chemokine CCL3 production. Glia 2015, 63:51-65.
11. Maezawa I., et al. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J. 2006, 20:797-799.
12. Maezawa I., et al. Apolipoprotein E isoform-dependent dendritic recovery of hippocampal neurons following activation of innate immunity. J. Neuroinflammation 2006, 3:21.
13. Li X., et al. Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia. FASEB J. 2015, 29:1754-1762.
14. Cruchaga C., et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 2013, 78:256-268.
15. Guerreiro R., et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 2013, 368:117-127.
16. Zhang B., et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013, 153:707-720.
17. Melchior B., et al. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2010, 2:e00037.
18. + inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J. Exp. Med. 2015, 212:287-295.
19. Wang Y., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015, 160:1061-1071.
20. Cantoni C., et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol. 2015, 129:429-447.
21. Poliani P.L., et al. TREM2 sustains microglial expansion during aging and response to demyelination. J. Clin. Invest. 2015, 125:2161-2170.
22. Wunderlich P., et al. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J. Biol. Chem. 2013, 288:33027-33036.
23. Schenk M., et al. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J. Clin. Invest. 2007, 117:3097-3106.
24. Weber B., et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathog. 2014, 10:e1003900.
25. Replogle J.M., et al. A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Ann. Neurol. 2015, 77:469-477.
26. Jiang T., et al. CD33 in Alzheimer's disease. Mol. Neurobiol. 2014, 49:529-535.
27. Bradshaw E.M., et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 2013, 16:848-850.
28. Griciuc A., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
29. Malik M., et al. CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. J. Neurosci. 2013, 33:13320-13325.
30. Bradt B.M., et al. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J. Exp. Med. 1998, 188:431-438.
31. Rogers J., et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol. Aging 2006, 27:1733-1739.
32. Shen Y., et al. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 2001, 305:165-168.
33. Lambert J.C., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
34. Chibnik L.B., et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann. Neurol. 2011, 69:560-569.
35. Biffi A., et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 2012, 78:334-341.
36. Luo J., et al. Meta-analysis of the association between CR1 polymorphisms and risk of late-onset Alzheimer's disease. Neurosci. Lett. 2014, 578:165-170.
37. Brouwers N., et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol. Psychiatry 2012, 17:223-233.
38. Bralten J., et al. CR1 genotype is associated with entorhinal cortex volume in young healthy adults. Neurobiol. Aging 2011, 32. 2106 e2107-2111.
39. Xu Q., et al. Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. J. Biol. Chem. 2000, 275:31770-31777.
40. Cole G.M., Ard M.D. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. Microsc. Res. Tech. 2000, 50:316-324.
41. Mulder S.D., et al. Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 2014, 62:493-503.
42. Lidstrom A.M., et al. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp. Neurol. 1998, 154:511-521.
43. Schrijvers E.M., et al. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011, 305:1322-1326.
44. DeMattos R.B., et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10843-10848.
45. Lancaster T.M., et al. Alzheimer's disease risk variant in CLU is associated with neural inefficiency in healthy individuals. Alzheimers Dement. 2014, Published online December 10, 2014. 10.1016/j.jalz.2014.10.012.
46. Elias-Sonnenschein L.S., et al. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort. PLoS ONE 2013, 8:e59676.
47. Desikan R.S., et al. The role of clusterin in amyloid-beta-associated neurodegeneration. JAMA Neurol. 2014, 71:180-187.
48. Karch C.M., et al. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS ONE 2012, 7:e50976.
49. Zhao Q.F., et al. ABCA7 in Alzheimer's disease. Mol. Neurobiol. 2015, 51:1008-1016.
50. Hollingworth P., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43:429-435.
51. Naj A.C., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43:436-441.
52. Shulman J.M., et al. Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol. 2013, 70:1150-1157.
53. Kim W.S., et al. Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. Neuroreport 2006, 17:891-896.
54. Kim W.S., et al. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J. Biol. Chem. 2005, 280:3989-3995.
55. Jehle A.W., et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J. Cell Biol. 2006, 174:547-556.
56. Kim W.S., et al. Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease. J. Neurosci. 2013, 33:4387-4394.
57. Proitsi P., et al. Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiol. Aging 2014, 35:279-290.
58. Eon Kuek L., et al. The MS4A family: counting past 1, 2 and 3. Immunol. Cell Biol. 2015, Published online April 3, 2015. 10.1038/icb.2015.48.
59. Koslowski M., et al. MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes. Cancer Res. 2008, 68:3458-3466.
60. McGeer P.L., et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
61. Yu L., et al. Association of brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol. 2015, 72:15-24.
62. Harms A.S., et al. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 2013, 33:9592-9600.
63. Han J., et al. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997, 386:296-299.
64. Johnson M.E., et al. A ChIP-seq-defined genome-wide map of MEF2C binding reveals inflammatory pathways associated with its role in bone density determination. Calcif. Tissue Int. 2014, 94:396-402.
65. Zhang Y., et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014, 34:11929-11947.
66. Zhang J., et al. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. 2000, 12:361-378.
67. Takeshita S., et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat. Med. 2002, 8:943-949.
68. Viernes D.R., et al. Discovery and development of small molecule SHIP phosphatase modulators. Med. Res. Rev. 2014, 34:795-824.
69. Lambert J.C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013, 45:1452-1458.
70. Peng Q., et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci. Signal. 2010, 3:ra38.
71. Bao M., et al. CD2AP/SHIP1 complex positively regulates plasmacytoid dendritic cell receptor signaling by inhibiting the E3 ubiquitin ligase Cbl. J. Immunol. 2012, 189:786-792.
72. Carrasquillo M.M., et al. Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. Neurobiol. Aging 2015, 36:60-67.
73. Wang H.F., et al. Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. J. Alzheimers Dis. 2015, 44:115-123.
74. Sakamoto A., et al. Expression profiling of the ephrin (EFN) and Eph receptor (EPH) family of genes in atherosclerosis-related human cells. J. Int. Med. Res. 2011, 39:522-527.
75. Frasca D., Blomberg B.B. Inflammaging decreases adaptive and innate immune responses in mice and humans. Biogerontology 2015, Published online April 29, 2015. 10.1007/s10522-015-9578-8.
76. Schafer D.P., et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
77. Wake H., et al. Microglia: actively surveying and shaping neuronal circuit structure and function. Trends Neurosci. 2013, 36:209-217.
78. Parkhurst C.N., et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 2013, 155:1596-1609.
79. Pocock J.M., Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci. 2007, 30:527-535.
80. Gosselin D., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 2014, 159:1327-1340.
81. Lavin Y., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014, 159:1312-1326.
82. Wes P.D., et al. Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. PLoS ONE 2014, 9:e106050.
83. Zilka N., et al. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J. Neuroimmunol. 2009, 209:16-25.
84. Yoshiyama Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
85. Streit W.J., et al. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118:475-485.
86. Lee D.C., et al. LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J. Neuroinflammation 2010, 7:56.
87. Kitazawa M., et al. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
88. Bhaskar K., et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010, 68:19-31.
89. Gorlovoy P., et al. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009, 23:2502-2513.
90. Li Y., et al. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
91. Heneka M.T., et al. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014, 14:463-477.
92. Hickman S.E., et al. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 2008, 28:8354-8360.
93. Krabbe G., et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE 2013, 8:e60921.
94. in t' Veld B.A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001, 345:1515-1521.
95. Stewart W.F., et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
96. Vlad S.C., et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008, 70:1672-1677.
97. Funk C.D., FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol. 2007, 50:470-479.
98. Liang X., et al. Neuronal and vascular protection by the prostaglandin E2 EP4 receptor in a mouse model of cerebral ischemia. J. Clin. Invest. 2011, 121:4362-4371.
99. Johansson J.U., et al. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J. Neurosci. 2013, 33:16012-16032.
100. Johansson J.U., et al. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J. Clin. Invest. 2015, 125:350-364.
101. Shi J., et al. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J. Immunol. 2010, 184:7207-7218.
102. Woodling N.S., et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J. Neurosci. 2014, 34:5882-5894.
103. Cho S.H., et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2011, 286:32713-32722.
104. Lee S., et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 2010, 177:2549-2562.
105. Fuhrmann M., et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 2010, 13:411-413.
106. Xue J., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014, 40:274-288.
107. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
108. Cagnin A., et al. In vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467.
109. 11C]PIB-PET study. Neurobiol. Dis. 2008, 32:412-419.
110. Kreisl W.C., et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 2013, 136:2228-2238.
111. 18F]-FEPPA. Mol. Psychiatry 2015, Published online February 24, 2015. 10.1038/mp.2015.1.
112. 11C]DAA1106. Psychiatry Res. 2012, 203:67-74.
113. 11C]DAA1106. Biol. Psychiatry 2008, 64:835-841.
114. Maze I., et al. Analytical tools and current challenges in the modern era of neuroepigenomics. Nat. Neurosci. 2014, 17:1476-1490.
115. Miller J.A., et al. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J. Neurosci. 2008, 28:1410-1420.
116. Miller J.A., et al. Genes and pathways underlying regional and cell type changes in Alzheimer's disease. Genome Med. 2013, 5:48.
117. Aubry S., et al. Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression. PLoS ONE 2015, 10:e0120352.
118. Villaverde A.F., Banga J.R. Reverse engineering and identification in systems biology: strategies, perspectives and challenges. J. R. Soc. Interface 2014, 11:20130505.
119. Augustin R., et al. Bioinformatics identification of modules of transcription factor binding sites in Alzheimer's disease-related genes by in silico promoter analysis and microarrays. Int. J. Alzheimers Dis. 2011, 2011:154325.
120. Chen J.C., et al. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 2014, 159:402-414.
121. Gjoneska E., et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 2015, 518:365-369.
122. Chibnik L.B., et al. Alzheimer's loci: epigenetic associations and interaction with genetic factors. Ann. Clin. Transl. Neurol. 2015, 2:636-647.
123. De Jager P.L., et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat. Neurosci. 2014, 17:1156-1163.
124. Lunnon K., et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat. Neurosci. 2014, 17:1164-1170.
125. Ossenkoppele R., et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013, 9:414-421.
126. Berti V., et al. PET/CT in diagnosis of dementia. Ann. N. Y. Acad. Sci. 2011, 1228:81-92.
127. Jacobs A.H., Tavitian B. Noninvasive molecular imaging of neuroinflammation. J. Cereb. Blood Flow Metab. 2012, 32:1393-1415.
128. Batarseh A., Papadopoulos V. Regulation of translocator protein 18kDa (TSPO) expression in health and disease states. Mol. Cell. Endocrinol. 2010, 327:1-12.
129. Chen M.K., Guilarte T.R. Translocator protein 18kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol. Ther. 2008, 118:1-17.
130. Ching A.S., et al. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging 2012, 3:111-119.
131. 11C]PK11195 positron emission tomography study. Neurobiol. Aging 2013, 34:128-136.
132. Wiley C.A., et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch. Neurol. 2009, 66:60-67.
133. 11C]PK11195 challengers. Eur. J. Nuclear Med. Mol. Imaging 2008, 35:2304-2319.
134. 18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients. J. Cereb. Blood Flow Metab. 2015, 35:766-772.
135. Guo Y., et al. Structure and activity of tryptophan-rich TSPO proteins. Science 2015, 347:551-555.
136. Li F., et al. Protein structure. Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism. Science 2015, 347:555-558.